A phase I trial in PD-L1 positive NSCLC with pembrolizumab (NCT02039674) is currently ongoing, as is a phase I/II trial with ipilimumab or chemotherapy in combination with pembrolizumab (NCT02039674) and a phase II trial of adjuvant pembrolizumab after chemo-radiotherapy for stage III NSCLC patients (NCT02343952) (Table 2). The gene discussed is CD274; the disease is non-small cell lung carcinoma.